Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10,209 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The European Treatment and Outcome Study score is associated with clinical outcomes and treatment response following European LeukemiaNet 2013 recommendations in chronic-phase chronic myeloid leukemia.
Iriyama N, Hatta Y, Kobayashi S, Uchino Y, Miura K, Kurita D, Kodaira H, Inoue M, Takei M. Iriyama N, et al. Among authors: kobayashi s. Int J Hematol. 2014 Oct;100(4):379-85. doi: 10.1007/s12185-014-1649-0. Epub 2014 Aug 5. Int J Hematol. 2014. PMID: 25092482 Clinical Trial.
An effective salvage treatment using ifosfamide, etoposide, cytarabine, dexamethasone, and rituximab (R-IVAD) for patients with relapsed or refractory aggressive B-cell lymphoma.
Miura K, Takei K, Kobayashi S, Kiso S, Hirabayashi Y, Hojo A, Kodaira H, Yagi M, Kurita D, Kobayashi Y, Tanaka T, Iriyama N, Hatta Y, Kura Y, Yamazaki T, Sawada U, Takeuchi J. Miura K, et al. Among authors: kobayashi y, kobayashi s. Int J Hematol. 2011 Jul;94(1):90-96. doi: 10.1007/s12185-011-0884-x. Epub 2011 Jun 23. Int J Hematol. 2011. PMID: 21695600
Efficacy of oral cytarabine ocfosfate and etoposide in the treatment of elderly patients with higher-risk myelodysplastic syndromes compared to that in elderly acute myeloid leukemia patients.
Horikoshi A, Iriyama N, Hirabayashi Y, Kodaira H, Matsukawa Y, Uchino Y, Takahashi H, Hatta Y, Takeuchi J, Kobayashi S, Miura K. Horikoshi A, et al. Among authors: kobayashi s. Chemotherapy. 2013;59(2):152-8. doi: 10.1159/000351114. Epub 2013 Sep 27. Chemotherapy. 2013. PMID: 24080768
Dose-intensified CHOP with rituximab (R-Double-CHOP) followed by consolidation high-dose chemotherapies for patients with advanced diffuse large B-cell lymphoma.
Kurita D, Miura K, Nakagawa M, Ohtake S, Sakagami M, Uchino Y, Takahashi H, Kiso S, Hojo A, Kodaira H, Yagi M, Hirabayashi Y, Kobayashi Y, Iriyama N, Kobayashi S, Hatta Y, Kura Y, Sugitani M, Takei M. Kurita D, et al. Among authors: kobayashi y, kobayashi s. Int J Hematol. 2015 Jun;101(6):585-93. doi: 10.1007/s12185-015-1780-6. Epub 2015 Mar 17. Int J Hematol. 2015. PMID: 25776837
Clinical efficacy and safety of arbekacin for high-risk infections in patients with hematological malignancies.
Miura K, Nakagawa M, Takahashi H, Uchino Y, Kodaira H, Iriyama N, Sakagami M, Ohtake S, Kobayashi S, Hojo A, Kurita D, Kobayashi Y, Kusuda M, Hirabayashi Y, Hatta Y, Takei M. Miura K, et al. Among authors: kobayashi y, kobayashi s. Int J Hematol. 2016 Mar;103(3):334-40. doi: 10.1007/s12185-015-1926-6. Epub 2015 Dec 29. Int J Hematol. 2016. PMID: 26715149 Clinical Trial.
Efficacy of a dose-intensified CHOP (Double-CHOP) regimen for peripheral T-cell lymphomas.
Iriyama N, Takahashi H, Hatta Y, Miura K, Kobayashi Y, Kurita D, Hirabayashi Y, Hojo A, Kodaira H, Yagi M, Kiso S, Uchino Y, Nakagawa M, Kusuda M, Kobayashi S, Horikoshi A, Kura Y, Yamazaki T, Sawada U, Takeuchi J. Iriyama N, et al. Among authors: kobayashi y, kobayashi s. Oncol Rep. 2013 Feb;29(2):805-11. doi: 10.3892/or.2012.2143. Epub 2012 Nov 15. Oncol Rep. 2013. PMID: 23166041
10,209 results
You have reached the last available page of results. Please see the User Guide for more information.